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ABSTRACT 1 
AIM: To document current practice by dietitians in Australia and Canada in the 2 
nutrition management of Parkinson’s disease. This will help to identify priority areas 3 
for review and development of practice guidelines and direct future research. 4 
METHODS: Current practice in the phases of the Nutrition Care Plan were captured 5 
using an online survey distributed to DAA members and PEN subscribers through 6 
their email newsletters. The results of the diagnosis, intervention and monitoring 7 
phases are presented here. 8 
RESULTS: Eighty-four dietitians responded. There was consistency in practice for 9 
nutrition issues that are encountered in other populations, such as malnutrition and 10 
constipation. There was more variation in practice in the nutrition issues that are 11 
more specific to Parkinson’s disease, such as nutrition and meal interactions with 12 
medication. A lack of awareness of emerging treatments, such as deep brain 13 
stimulation (DBS) surgery, appears to exist in the responding dietitians. 14 
CONCLUSIONS: The variation in practice that was present for the nutrition issues 15 
specific to Parkinson’s disease may reflect the lack of quality evidence and 16 
subsequently evidence-based guidelines in these areas. Work to provide background 17 
information about treatment options and to translate current evidence for the nutrition 18 
issues that are specific to Parkinson’s disease into practice recommendations should 19 
be completed.  20 
 21 
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INTRODUCTION 1 
Parkinson’s disease (PD) is characterised by a number of movement or motor 2 
(bradykinesia, akinesia, resting tremor, muscle rigidity and postural instability) and 3 
non-motor symptoms (depression, anxiety, dementia, loss of olfactory sense, 4 
dysphagia, slowed gastric motility, orthostatic hypotension). The manifestation and 5 
severity of these symptoms varies between individuals and treatments and over the 6 
course of the disease.(1) At the later stages of this progressive disease (indicated by 7 
a higher value on the Hoehn & Yahr scale,(2) ranging from 1 – 5), these symptoms 8 
can result in considerable disability. 9 
Dopamine replacement therapy, in the form of levodopa, is commonly used for motor 10 
symptom management.(3) Levodopa is commonly prescribed in multiple doses 11 
throughout the day to ensure a consistent therapeutic effect. Initially, side effects can 12 
include nausea(3) and vomiting(4) which typically subside after continued use. Long-13 
term use can result in a delayed or absent response resulting in motor and non-motor 14 
fluctuations (“off” periods) during which symptoms are not optimally controlled.(3,5) In 15 
advanced disease, greater disease severity and increases in medication dosage may 16 
increase the amount of time spent in an “off” state as the therapeutic window 17 
becomes shorter.(6,7) At the same time, prolonged use can also result in dyskinesias 18 
or involuntary movements.(3,8) When medication is no longer effectively controlling 19 
symptoms and/or maintaining a suitable quality of life, deep brain stimulation (DBS) 20 
surgery can be considered for symptom management.(9)  21 
Consumption of levodopa with meals can delay its absorption at the jejuno-duodenal 22 
border due to slowed gastric motility.(10) Absorption can also be influenced by amino 23 
acids in food, which compete for the same saturable mucosal transport 24 
mechanisms.(11) Waiting 30-45 minutes to eat a meal following each levodopa 25 
dosage may improve the transit to the absorption site(10) while modified protein diets 26 
have been suggested to help manage any potential competitive absorption. These 27 
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modified protein diets include low protein diets,(12,13) protein redistribution diets (PRD) 1 
where the majority of protein is consumed in the evening in order to maximise the 2 
effectiveness of medication during the daytime hours,(11) and specific ratios of protein 3 
to carbohydrate intake(14) such as a ratio of CHO:protein at 7:1 or 5:1 again to 4 
manage overall protein intake.  5 
Nutrition management of PD may involve the management of medication and food 6 
interactions(10,11); overweight/obesity, which may be due to altered taste,(15,16) 7 
medications(17) and surgical options(18); malnutrition,(19–22) which can be related to the 8 
range of symptoms and medical treatments that may influence energy intake and 9 
expenditure(23,24); possible nutrient deficiencies;(25,26) and constipation(27) that can 10 
result from slowed gastric motility and the use of some medications. Nutrition 11 
diagnosis, intervention and monitoring as part of Medical Nutrition Therapy (MNT) for 12 
these issues should be evidence-based in order to provide consistent and effective 13 
care.  14 
In the absence of comprehensive evidence-based guidelines for nutrition 15 
management of Parkinson’s disease, investigating current nutrition-related practice 16 
will identify priority areas for review and development of practice guidelines and 17 
direct future research. The primary aim of this study was to document current 18 
practice in nutrition diagnosis, intervention and monitoring as part of the nutritional 19 
management of people with Parkinson’s disease (PWP) by dietitians located in 20 
Australia and Canada.  A secondary aim was to collect data for the prioritisation of 21 
practice questions, including nutrition-related information that would be useful for 22 
dietitians to manage their patients/clients’ condition and questions effectively.  23 
METHODS 24 
An online survey was distributed to members of DAA and PEN via their respective 25 
email newsletters. Informed consent was obtained as per protocol approved by the 26 
Queensland University of Technology Human Research Ethics Committee. Details of 27 
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the survey are described in detail elsewhere.(28) Briefly, the questions in Key Survey 1 
were presented within the 4 phases of the nutrition care plan (NCP): Nutrition 2 
Assessment, Nutrition Diagnosis, Nutrition Intervention and Nutrition 3 
Evaluation/Monitoring.(29) DAA members had 10 weeks, and PEN subscribers 4 4 
weeks, to respond.  5 
Survey 6 
The results of the questions relating to nutrition assessment are published 7 
separately.(28) The nutrition diagnosis, intervention and monitoring and evaluation 8 
aspects of treatment were covered in 15 questions, including both multiple choice 9 
and open-ended questions. In the multiple-choice questions, there was an “Other” 10 
option, which allowed the respondents to type an alternative answer. Respondents 11 
were able to provide more than one response to the majority of questions. 12 
The first of the 15 questions included twelve typical nutrition diagnoses described in 13 
standardized language (International Dietetics and Nutrition Terminology (IDNT)(30), 14 
using problem, etiology, signs and symptoms or PESS statements.(31) Typical 15 
nutrition interventions (n=11) included malnutrition (undernutrition), over-nutrition, 16 
macronutrient intake, modified texture diets, nutrition supplements, management of 17 
non-motor symptoms and practice based on medical and surgical (including DBS) 18 
management. Monitoring and evaluation questions (n=3) included monitoring 19 
frequency and primary outcome measures.  20 
An additional 2 questions collected information about typical nutrition related 21 
questions that the dietitians had received from their Parkinson’s disease 22 
patients/clients and resources or information that the dietitians had not been able to 23 
find when managing their patients/clients with Parkinson’s disease. 24 
Statistical analyses 25 
Open-ended responses and those provided in the “Other” response choice were 26 
reviewed and categorised according to the researcher’s judgment. If the written 27 
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response was considered to be similar to an existing answer, it was included in the 1 
frequency reporting in that response option rather than in the “Other” category. For 2 
example, in the question regarding the frequency of monitoring, some respondents 3 
did not choose a multiple-choice response and instead wrote in the “Other” response: 4 
“stage of disease”, “hours available to see residents”, and “severity of nutritional 5 
diagnosis”. These were categorised under the multiple-choice responses “Stage of 6 
disease”, “Resources”, and “Nutritional diagnosis”, respectively.  7 
Results are presented as frequencies, and percentages may not total 100% for those 8 
questions where multiple responses were allowed.  9 
RESULTS 10 
Respondents (n=84, response rate 1%) were predominantly from Australia (n=67, 11 
79.8%) with 59.5% (n=50) working for more than 5 years.(28) Less than 1 year of 12 
experience was reported by 9.5% (n=8). Most (n=74, 88.1%) reported working <25% 13 
of their time with PWP, and 79.8% reported a medium-high level of confidence in the 14 
nutrition management of PD. The majority (n=59, 70.2%) worked in a clinical (acute 15 
care) setting, followed by aged care (n=24, 28.6%), and 33.3% (n=28) reported 16 
working in more than one practice area. “Other” practice area responses included 17 
management, corporate, rehabilitation and mental health. 18 
The most frequently reported nutrition diagnoses were related to 19 
malnutrition/unintended weight loss (n=62, 73.8%), swallowing difficulties (n=60, 20 
71.4%), protein intake (n=54, 64.3%) and fibre intake (n=41, 48.8%) (Table 1). The 21 
least commonly used diagnoses were those related to weight gain.  22 
Stage of disease affected the choice of intervention strategies for 64.3% of the 23 
responding dietitians. High energy, high protein (HEHP) diets were the most 24 
commonly used for malnutrition (Table 2). A balanced eating plan was most 25 
commonly reported for achieving weight loss (Table 2). The use of protein intake 26 
recommendations for gender and age was the most often reported. “Other” 27 
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responses included an even distribution of protein throughout the day (n=5, 6.0%), 1 
recommendations based on stage of disease (n=2, 2.4%), 0.9 – 1.1 g/kg/day (n=1, 2 
1.2%) and not enough confidence to make specific recommendations (n=1, 1.2%). 3 
Difficulty swallowing was the most commonly reported reason for modified texture 4 
diets (Table 2). The majority recommended the use of high fibre diets (86.9%) for 5 
constipation (Table 2). The main “other” response included ensuring adequate 6 
hydration (n=81, 96.4%).  7 
Nearly half (n=41, 48.8%) reported recommending taking PD medications 30 – 120 8 
minutes before or after a meal, 16.7% (n=14) advised separating medications from 9 
meals without a specific time, 27.4% (n=23) did not make recommendations, and six 10 
(n=6, 7.1%) followed recommendations provided by a medical practitioner. This was 11 
an open-ended free text question, and 3 (3.6%) of the respondents wrote that this 12 
was the responsibility of the medical practitioner and 2 (2.4%) responded that 13 
recommendations were made to patients only if directed by their medical practitioner. 14 
A third of respondents (n=30, 35.7%) had not seen patients with or not heard of DBS 15 
surgery. Of those who had, 58.3% (n=49) did not make specific nutrition-related 16 
recommendations. Of those that made recommendations for their patients with DBS, 17 
3 (3.6%) responded that they monitored weight gain and 1 (1.2%) reported relaxing 18 
recommendations because of improved functional state following surgery. 19 
When asked if there were any other interventions that were routinely used, 2 (2.4%) 20 
responded strength training or physiotherapy, 2 (2.4%) responded the use of 21 
adaptive cutlery, 1 (1.2%) responded social eating, and 1 (1.2%) responded limiting 22 
carbohydrate loads after meals to manage post-prandial hypotension. 23 
The frequency of monitoring was mostly determined by the nutrition diagnosis (Table 24 
3). The most commonly reported outcome measure was related to appropriate weight 25 
changes (n=82, 97.6%). “Other” outcome measures included compliance with texture 26 
modified diets (n=3) and adequate fluid intake (n=2). 27 
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Dietitians reported that client/patients requested information on low protein 1 
diets/protein and medication interactions (n=25, 29.8%), dysphagia management 2 
(n=18, 21.4%), the need for a specific diet (n=13, 15.5%), prevention of weight loss 3 
(n=12, 14.3%), constipation management (n=12, 14.3%), use of 4 
vitamins/supplements or certain foods (n=8, 9.5%), enteral feeding management 5 
(n=5, 6.0%) and a curative diet (n=4, 4.8%). Information indicated as useful but 6 
difficult to find by dietitians included the appropriate timing of protein/protein 7 
distribution (n=7, 8.3%), protein requirements/protein restriction (n=6, 7.1%), 8 
CHO:protein ratios (n=5, 6.0%), timing of medication and food (n=5, 6.0%), and 9 
estimated energy requirements to account for symptoms (n=4, 4.8%).  10 
DISCUSSION 11 
This study accompanies a paper reporting nutrition assessment practice by 12 
Australian and Canadian dietitians(28) and provides insight into current practice in the 13 
remainder of the Nutrition Care Process phases, namely Diagnosis, Intervention and 14 
Monitoring. There were a number of reported nutrition-related issues that were 15 
common for all Nutrition Care Process phases including weight loss/malnutrition, 16 
concerns about protein intake, dysphagia and constipation. These reflect the 17 
nutrition-related issues that have been previously reported as common for people 18 
with Parkinson’s disease.(32–34)  19 
In the current survey, information on these topics was requested by patients/clients, 20 
and dietitians also requested more scientific information. There was consistency 21 
among the dietitians in the reported nutrition diagnoses but inconsistencies existed in 22 
the assessment and intervention phases. Because the information gathered in the 23 
assessment phase provides the basis for the intervention phase, differences in the 24 
assessment phase could potentially result in varying intervention priorities and plans.   25 
The intent of evidence-based guidelines is to remove unnecessary and inappropriate 26 
variations in practice and to improve patient outcomes. Reported barriers to 27 
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incorporating evidence into dietetic practice include a lack of time to read and 1 
evaluate the evidence(35–38) in addition to a lack of confidence in critical analysis 2 
skills.(35,37,38) According to surveyed dietitians, the best way to move towards 3 
evidence-based practice is to develop and provide evidence-based guidelines or 4 
protocols.(35) When available, dietitians routinely refer to guidelines and find them 5 
useful.(39) The common diagnoses reported here can provide direction in the 6 
prioritisation of guideline development for the nutrition management of PD.  7 
Malnutrition, in addition to being the most commonly diagnosed nutrition-related 8 
problem in this survey, is a documented issue in PWP, with approximately 15% 9 
malnourished(19) and up to 34% at risk of malnutrition in the community.(21,22)  10 
The use of a high protein, high energy (HPHE) diet in malnourished PWP may 11 
interfere with the levodopa in dopaminergic medication,(40)  and there is limited 12 
evidence to support an HPHE intervention.(41) Despite this, an HPHE approach was 13 
used by the majority of the responding dietitians, perhaps indicating a higher priority 14 
for the management of malnutrition than on the potential benefit of limiting protein on 15 
medication effectiveness.  16 
Furthermore, the use of either protein redistribution diets or specific 17 
carbohydrate:protein ratios was limited despite recommendations that they may be 18 
useful.(11) Dietitians and patients/clients indicated a desire for more information about 19 
and recommendations for the appropriate protein intake and interactions with 20 
medication. In light of this, providing guidance in this area should be a priority.  21 
A similar issue is the separation of levodopa and meals. One relatively simple 22 
strategy for improving levodopa effectiveness is to separate it from meals, either 23 
approximately 30-40 minutes before or 60-120 minutes following a meal.(32,33,42,43) 24 
There was considerable variation in practice, ranging from no recommendation to a 25 
wide range of recommended times. Responses from several dietitians indicated a 26 
belief that this is outside the scope of dietetic practice. Therefore, incorporating this 27 
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into guidelines regarding food and medication interactions may improve dietitians’ 1 
confidence in providing information that could improve patient outcomes without 2 
limiting specific macronutrients. 3 
On the other hand, the least common diagnoses were related to weight gain, with 4 
30% reporting that they did not see clients/patients for weight gain/over-nutrition. 5 
Similarly to the general population, over-nutrition has been reported in approximately 6 
60% of PWP.(44) Overweight/obesity may become more common with the increasing 7 
use of DBS surgery as a treatment option, following which weight gain is reported.(18) 8 
About 30% of the respondents was not familiar with the surgery. Therefore, while 9 
nutrition-related DBS guidelines may not be immediately necessary due to the low 10 
exposure, providing background information will help to raise awareness about 11 
treatment options and their potential side effects.  12 
Parkinson’s disease is a progressive disease, and the stage of disease influenced 13 
intervention decisions for a majority of dietitians. This should be considered when 14 
developing evidence-based statements, and guidelines may need to be divided by 15 
disease stage. 16 
The questionnaire was not able to capture the full extent of nutrition management in 17 
PD nor did it document all of the possible variations in practice. The use of multiple-18 
choice questions may have prevented some responses. Despite this limitation, this is 19 
the first report of dietetic practice in PD and helps to guide the prioritisation and 20 
development of guidelines.  21 
The low response rate of both Australian and Canadian dietitians may limit the 22 
generalisability of these results to dietetic practice. However, this may also reflect the 23 
extent to which Parkinson’s disease is being managed by nutrition professionals. To 24 
decrease the participant burden, the majority of the questionnaire included the 25 
selection of pre-chosen answers in the form of multiple-choice questions. The 26 
answers that were available may not have reflected the range diagnoses and 27 
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interventions that are used in practice.  1 
Due to the range and individual variation of Parkinson’s disease symptoms, along 2 
with the various forms of treatment, there are a number of complex nutritional issues 3 
to be managed in PD. Practice guidelines for the nutrition-related management of PD 4 
should focus first on the most common diagnoses and patient questions while 5 
providing background information on treatment options and their side effects. Future, 6 
similar surveys may be necessary to monitor changes in priorities as PD treatment 7 
evolves. 8 
 9 
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Table 1: Reported practice in the nutrition diagnosis phase of the Nutrition Care Plan (NCP) by 84 dietitians listed in order of 
decreasing frequency 
 n (%) 
1. (P) Increased energy expenditure (E) involuntary physical activity/movement (SS) 
Parkinson's disease and/or unintentional weight loss. 62 (73.8) 
2. (P) Swallowing difficulty (E) motor causes (Parkinson's disease) (SS) coughing, choking, 
prolonged chewing, feeling of 'food getting stuck' and by avoidance of foods. 60 (71.4) 
3. (P) Inadequate energy intake (E) increased energy requirements (SS) failure to gain or 
maintain appropriate weight. 54 (64.3) 
4. (P) Inadequate fibre intake (E) difficulty chewing or swallowing high-fibre foods (SS) 
estimated intake of fibre that is insufficient when compared to recommended amounts. 41 (48.8) 
5. (P) Malnutrition (E) physiological causes increasing nutrient needs (SS) BMI 10% in 6 
months or >5% in 1 month/underweight with muscle wasting. 39 (46.4) 
6. (P) Inadequate protein intake (E) difficulty chewing or swallowing high protein foods (SS) 
adherence to a low-protein symptom management diet. 34 (40.5) 
7. (P) Malnutrition (E) physiological changes resulting in presence of nutrition impact 
symptoms (SS) >10% weight loss in 6 months or >5% in 1 month/underweight with muscle 
wasting. 
33 (39.3) 
8. (P) Malnutrition (E) food-and nutrition-related knowledge deficit concerning amount of 
energy and amount and type of dietery protein (SS) >10% weight loss in 6 months or >5% 
in 1 month/underweight with muscle wasting. 
32 (38.1) 
9. (P) Inadequate fibre intake (E) lack of or limited access to fibre-containing foods/fluids 
(SS) estimated intake of fibre that is insufficient when compared to recommended amounts. 30 (35.7) 
10. (P) Inadequate energy intake (E) lack of access to food (SS) failure to gain or maintain 
appropriate weight. 30 (35.7) 
11. (P) Altered gastrointestinal function (E) changes in the GI tract motility (SS) abdominal 
distension and abdominal pain. 28 (33.3) 
12. (P) Inadequate protein intake (E) food- and nutrition-related knowledge deficit 
concerning amount of protein (SS) prolonged adherence to a low-protein symptom 
management diet. 
20 (23.8) 
13. (P) Malnutrition (E) beliefs about protein interaction with medication (SS) >10% weight 
loss in 6 months or >5% in 1 month/underweight with muscle wasting. 17 (20.2) 
14. (P) Excessive energy intake (E) food-and-nutrition related knowledge deficit concerning 
energy intake (SS) weight gain/BMI >25kg/m2 6 (7.1) 
15. (P) Excessive energy intake (E) medications that increase appetite and/or increase 
compulsive eating behaviours (SS) weight gain/BMI >25kg/m2. 5 (6.0) 
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Other 5 (6.0) 
 (P)=problem; (E)= etiology; (SS)=signs and symptoms 
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Table 2: Reported practice in the nutrition intervention phase of the Nutrition Care Plan 
(NCP) by 84 dietitians in Australia and Canada reported as frequency (%) 
 n (%) 
Strategies for managing malnutrition  
High energy, low protein 8 (9.5) 
High energy, moderate protein 12 (14.2) 
High energy, high protein 69 (82.1) 
Do not address 0 (0) 
Other 2 (2.4) 
Strategies for weight loss  
Balanced eating 56 (66.7)* 
High protein/low carbohydrate 5 (6.0) 
Low protein/high carbohydrate 3 (3.6) 
Meal replacements 1 (1.2) 
Do not address 26 (31.0)* 
Other 6 (7.1) 
Dietary protein recommendations  
Low protein 1 (1.2) 
Protein redistribution diet 10 (11.9) 
Carbohydrate:protein 7:1 6 (7.1) 
Carbohydrate:protein 6:1 0 (0) 
Carbohydrate:protein 5:1 3 (3.6) 
Carbohydrate:protein 4:1 2 (2.4) 
Protein for gender/age 58 (69.0) 
Do not advise 16 (19.0) 
Other 9 (10.7) 
Strategies for constipation  
High fibre diet 71 (84.5) 
High fibre supplements 37 (44.0)* 
Probiotics 20 (23.8) 
Prescription medication 22 (26.2) 
Non-prescription medication 25 (29.8) 
Do not advise 2 (2.4) 
Other 38 (45.2) 
Reasons for Texture Modification(TM)  
Poor dentition 60 (71.4) 
Difficulties swallowing 78 (92.9) 
Difficulty cutting food 43 (51.2)* 
Difficulty moving food from plate/bowl to mouth 38 (45.2) 
Do not have patients/clients on TM diets 7 (8.3) 
Other 2 (2.4) 
*Significant difference between country of practice, p<.05 
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Table 3: Reported practice in the nutrition monitoring phase of the Nutrition Care Plan 
(NCP) by 84 dietitians in Australia and Canada reported as frequency (%) 
 n (%) 
Factors affecting frequency of monitoring  
Resources 40 (47.6) 
Location of clients 35 (41.7) 
Stage of disease 52 (61.9) 
Nutritional diagnosis 59 (70.2) 
Other 9 (10.7) 
Outcome measures  
Appropriate weight change 82 (97.6) 
Meets macronutrient requirements 64 (76.2) 
Meets micronutrient requirements 30 (35.7) 
Consumes supplements 59 (70.2) 
Regular bowel movements 74 (88.1) 
Parkinson’s disease symptom control 54 (64.3) 
Other 8 (9.5) 
 
